Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 3 Lung Neoplasms 3 Esophageal Neoplasms 3 Carcinoma, Non-Small-Cell Lung 3 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Triple Negative Breast Neoplasms 1 Stomach Neoplasms 1 Prostatic Neoplasms 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Non-Small Cell Lung Cancer Metastatic 1 Neoplasms 1 Melanoma 1 Head and Neck Neoplasms 1 Gastrointestinal Neoplasms 1 Endometrial Neoplasms 1

Interventions

pembrolizumab 20 Bevacizumab 14 Carboplatin 12 Standard of Care 10 Nivolumab 9 Cyclophosphamide 9 Cetuximab 8 Pemetrexed 7 Exercise 7 Doxorubicin 7 durvalumab 6 atezolizumab 6 Temozolomide 6 Radiotherapy 6 Prednisone 6 Paclitaxel 6 Cisplatin 6 Blood Specimen Collection 6 abemaciclib 5 Fluorouracil 5 130-nm albumin-bound paclitaxel 5 olaparib 4 dostarlimab 4 Rituximab 4 Leucovorin 4 Gemcitabine 4 Fulvestrant 4 Docetaxel 4 Dexamethasone 4 venetoclax 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasms × patritumab deruxtecan × 30 days × Clear all

NCT06941272 2026-05-12

MK-9999-01C

Merck Sharp & Dohme LLC

Phase 1/2 Recruiting

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡